IFNA2 and cancer: While IFN-α2 treatment remains the only viable option for SLFN12 stimulation, further studies would be required to move to a clinical-based setting, as its administration differs between our in vitro setting (5500 IU/mL) compared to cancer therapy treatments at (9 million U subcutaneously) up to three times a week [10,24,25].